BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9409334)

  • 1. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group.
    Mathew NT; Asgharnejad M; Peykamian M; Laurenza A
    Neurology; 1997 Dec; 49(6):1485-90. PubMed ID: 9409334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
    Klassen A; Elkind A; Asgharnejad M; Webster C; Laurenza A
    Headache; 1997; 37(10):640-5. PubMed ID: 9439085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
    Göbel H; Winter P; Boswell D; Crisp A; Becker W; Hauge T; Mihout B; Niewold J; Tørring J
    Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group.
    Havanka H; Dahlöf C; Pop PH; Diener HC; Winter P; Whitehouse H; Hassani H
    Clin Ther; 2000 Aug; 22(8):970-80. PubMed ID: 10972633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
    Heywood J; Bomhof MA; Pradalier A; Thaventhiran L; Winter P; Hassani H
    Cephalalgia; 2000 Jun; 20(5):470-4. PubMed ID: 11037743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
    Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
    Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
    Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
    Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.
    Newman L; Mannix LK; Landy S; Silberstein S; Lipton RB; Putnam DG; Watson C; Jöbsis M; Batenhorst A; O'Quinn S
    Headache; 2001 Mar; 41(3):248-56. PubMed ID: 11264684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
    Ashcroft DM; Millson D
    Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
    Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
    Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naratriptan.
    Massiou H
    Curr Med Res Opin; 2001; 17 Suppl 1():s51-3. PubMed ID: 12463278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group.
    Bomhof MA; Heywood J; Pradalier A; Enahoro H; Winter P; Hassani H
    Cephalalgia; 1998 Jan; 18(1):33-7. PubMed ID: 9601622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.
    Sheftell F; O'Quinn S; Watson C; Pait D; Winter P
    Headache; 2000 Feb; 40(2):103-10. PubMed ID: 10759909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study.
    Stronks DL; Tulen JH; Bussmann HB; Mulder LJ; Passchier J
    Headache; 2003 Sep; 43(8):845-52. PubMed ID: 12940805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naratriptan: an alternative for migraine.
    Dulli DA
    Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
    Lipton RB; Pascual J; Goadsby PJ; Massiou H; McCarroll KA; Vandormael K; Jiang K; Lines CR
    Headache; 2001 Sep; 41(8):754-63. PubMed ID: 11576198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan.
    Stark S; Spierings EL; McNeal S; Putnam GP; Bolden-Watson CP; O'Quinn S
    Headache; 2000; 40(7):513-20. PubMed ID: 10940089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous naratriptan on forearm blood flow.
    Yogendran L; Boswell D; Nacci P; Winter P
    Cephalalgia; 1998 Sep; 18(7):476-80. PubMed ID: 9793700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rizatriptan: an update of its use in the management of migraine.
    Wellington K; Plosker GL
    Drugs; 2002; 62(10):1539-74. PubMed ID: 12093318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
    Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
    Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.